Cybin Corp.

NEO: CYBN

Company Logo

Company Overview

Cybin Corp. is focused on furthering the research and development of psilocybin through its wholly-owned subsidiary, Serenity Life Sciences Inc., and developing proprietary medicinal mushroom products through its wholly-owned subsidiary, Natures Journey Inc. 

The company's IP strategy revolves around psychedelic delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new drug formulations, and protocol regiments. Its experienced management team has run multiple clinical trials and successfully brought many new drugs to market in the past.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.26

Diluted EPS (ttm)

Management Team

Mr. Douglas L. Drysdale
Chief Exec. Officer

Mr. Eric So
Co-Founder, Pres & Director

Mr. Paul Glavine
Co-Founder, COO & Director

Mr. John Kanakis
Co-Founder & Sr. VP of Bus. Devel.

Mr. Greg Cavers
Chief Financial Officer

Dr. Alex L. Nivorozhkin Ph.D.
Chief Scientific Officer

Lori Challenger
Director of Operations & Compliance

Sara Brittany Somerset
Chief Communications Officers

Ms. Jacqueline Poriadjian-Asch
Chief Marketing Officer

Dr. Eric Hoskins
Director & Gov. Relations Advisor

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization

Shares Outstanding
0

Shares Short (% of Float)
0 (0%)

Insider Ownership
0%